The statistic shows the distribution of the drug production value of antineoplastics in Japan in 2016, broken down by sub therapeutic category. In 2016, the production value of other antineoplastics made up the largest share with approximately 80.5 percent of the total production value, followed by antimetabolites with almost eleven percent.
Drug production value share of antineoplastics Japan 2016, by category
Distribution of the drug production value of antineoplastics in Japan in 2016, by sub therapeutic category
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Further Content: You might find this interesting as well
Statistics
- Production value of antineoplastics Japan 2015, by category
- Drug production value share of dermatologic preparations Japan 2018, by category
- Drug production value share Japan 2016, by drug form
- Production value extracorporeal diagnostic agents Japan 2016, by category
- Drug production value share of extracorporeal diagnostic age Japan 2016, by category
- Drug production value share of antibiotics Japan 2016, by category
- Drug production value of dermatologic preparations Japan 2018, by category
- Drug production value share of hormones Japan 2016, by category
- Drug production value of traditional Chinese medicines Japan 2012-2016, by category
- Drug production value blood and body fluid agents Japan 2016, by category
- Drug production value share of blood and body fluid agents Japan 2016, by category
- Sawai Pharmaceutical's total assets FY 2009-2018
- Nichi-Iko's R&D expenditure FY 2012-2018
- Japan's prescription drug market size 2008-2017
- US adults impression of the US pharma industry by age 2017
- First biosimilar marketing initiatives by MCOs in U.S. 2015
- US adults on research results impact on U.S. pharma industry by gender 2017
- Amount of cannabinoids needed to make pharmaceutical-grade compounds in 2017
- US adults' rating of impact of technology on U.S. pharma industry by gender 2017
Further related statistics
MHLW (Japan). (September 20, 2018). Distribution of the drug production value of antineoplastics in Japan in 2016, by sub therapeutic category [Graph]. In Statista. Retrieved December 12, 2019, from https://www.statista.com/statistics/740486/drug-production-value-share-of-antineoplastics-by-category-japan/
MHLW (Japan). "Distribution of the drug production value of antineoplastics in Japan in 2016, by sub therapeutic category." Chart. September 20, 2018. Statista. Accessed December 12, 2019. https://www.statista.com/statistics/740486/drug-production-value-share-of-antineoplastics-by-category-japan/
MHLW (Japan). (2018). Distribution of the drug production value of antineoplastics in Japan in 2016, by sub therapeutic category. Statista. Statista Inc.. Accessed: December 12, 2019. https://www.statista.com/statistics/740486/drug-production-value-share-of-antineoplastics-by-category-japan/
MHLW (Japan). "Distribution of The Drug Production Value of Antineoplastics in Japan in 2016, by Sub Therapeutic Category." Statista, Statista Inc., 20 Sep 2018, https://www.statista.com/statistics/740486/drug-production-value-share-of-antineoplastics-by-category-japan/
MHLW (Japan), Distribution of the drug production value of antineoplastics in Japan in 2016, by sub therapeutic category Statista, https://www.statista.com/statistics/740486/drug-production-value-share-of-antineoplastics-by-category-japan/ (last visited December 12, 2019)